Evidence map›Paper›PMID 36987378›Full record

ArticleAmerican journal of men's health

Risk Awareness and Demographic Characteristics Associated With the Use of Sexual Enhancement Supplements Among University Staff: A Cross-Sectional Study in the United Arab Emirates.

Ammar Abdulrahman Jairoun, Sabaa Saleh Al-Hemyari, Moyad Shahwan, Balsam Qubais Saeed, Brian Godman, Amanj Kurdi, Samer H Zyoud, Baharudin Ibrahim

Open access · goldAbstract read
In one paragraph

Article in American journal of men's health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 5 countries.

Ammar Abdulrahman JairounHealth and Safety Department, Dubai Municipality, Dubai, UAE.ORCID 0000-0002-4471-0878
Sabaa Saleh Al-HemyariPharmacy Department, Emirates Health Services, Dubai, UAE.
Moyad ShahwanDepartment of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, UAE.
Balsam Qubais SaeedClinical Science Department, College of Medicine, University of Sharjah, Sharjah, UAE.
Brian GodmanCentre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, UAE.
Amanj KurdiStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
Samer H ZyoudDepartment of Mathematics and Sciences, Ajman University, Ajman, UAE.
Baharudin IbrahimFaculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.
Ajman University · AEDubai Health Authority · AEHawler Medical University · IQUniversity of Malaya · MYUniversity of Sharjah · AEUniversity of Strathclyde · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sexual enhancement supplements (SESs) that have illegal additions of pharmaceuticals or analogues pose a significant health risk, particularly with long-term usage. When supplements are adulterated with phosphodiesterase type 5 (PDE-5) inhibitors, dosages can vary widely and there may be an increase in adverse effects and drug-drug interactions which cannot be avoided. Consequently, there is a need to evaluate the public risk awareness toward SES and the associated adverse events as well as explore significant factors associated with knowledge and risk awareness. A cross-sectional community-based study was conducted among University male students and staff at Ajman University, United Arab Emirates (UAE), using a self-administered survey via a web-based electronic link to explore key issues. A total of 1,101 male subjects participated in the study and completed the questionnaire. Four hundred and thirty-three(39.3%) (95% confidence interval [CI]: 33.2-44.5) participants reported using SES products. Of these, 137 (31.6%) [95% CI: 28.6-37.2] experienced adverse effects from SES product use. SES use was more prevalent among participants aged 60 to 69 years (odds ratio [OR]: 2.94; 95% CI: 1.63-5.28), diabetic patients (OR: 2.61; 95% CI: 1.75-3.90), hypertension patients (OR: 2.12; 95% CI: 1.45-3.1), and those overweight or obese (OR: 1.84; 95% CI: 1.44-2.35). This study indicates that SES is a popular practice among the UAE university staff and students. However, there is a need to implement risk awareness programs to raise public awareness regarding SES use and safety. Regulatory bodies are encouraged to provide additional advice on the proper use and possible risks of consuming SES.

Indexed as

Drug-Related Side Effects and Adverse ReactionsStudentsCross-Sectional StudiesDemographyHumansMaleSurveys and QuestionnairesUnited Arab EmiratesUniversitieserectile dysfunctionrisk awarenesssexual enhancement supplementside effectsUAE

Identifiers

PMID36987378
PMCPMC10061647
OpenAlexW4361297888

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.